Role of common mental and physical disorders in partial disability around the world
- PMID: 22539779
- PMCID: PMC3365273
- DOI: 10.1192/bjp.bp.111.097519
Role of common mental and physical disorders in partial disability around the world
Abstract
Background: Mental and physical disorders are associated with total disability, but their effects on days with partial disability (i.e. the ability to perform some, but not full-role, functioning in daily life) are not well understood.
Aims: To estimate individual (i.e. the consequences for an individual with a disorder) and societal effects (i.e. the avoidable partial disability in the society due to disorders) of mental and physical disorders on days with partial disability around the world.
Method: Respondents from 26 nationally representative samples (n = 61 259, age 18+) were interviewed regarding mental and physical disorders, and day-to-day functioning. The Composite International Diagnostic Interview, version 3.0 (CIDI 3.0) was used to assess mental disorders; partial disability (expressed in full day equivalents) was assessed with the World Health Organization Disability Assessment Schedule in the CIDI 3.0.
Results: Respondents with disorders reported about 1.58 additional disability days per month compared with respondents without disorders. At the individual level, mental disorders (especially post-traumatic stress disorder, depression and bipolar disorder) yielded a higher number of days with disability than physical disorders. At the societal level, the population attributable risk proportion due to physical and mental disorders was 49% and 15% respectively.
Conclusions: Mental and physical disorders have a considerable impact on partial disability, at both the individual and at the societal level. Physical disorders yielded higher effects on partial disability than mental disorders.
Conflict of interest statement
R.C.K. has been a consultant for GlaxoSmithKline, Kaiser Permanente, Pfizer, Sanofi-Aventis, Shire Pharmaceuticals and Wyeth-Ayerst; has served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst; and has had research support for his epidemiological studies from Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Pharmaceuticals, Pfizer and Sanofi-Aventis.
Figures
References
-
- Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med 2004; 46: 398–412 - PubMed
-
- Lerner D, Allaire SH, Reisine ST. Work disability resulting from chronic health conditions. J Occup Environ Med 2005; 47: 253–64 - PubMed
-
- Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med 1997; 27: 861–73 - PubMed
-
- Dewa C, Lin E. chronic physical illness, psychiatric disorder and disability in the workplace. Soc Sci Med 2000; 51: 41–50 - PubMed
-
- Dewa CS, Lesage A, Goering P, Caveen M. Nature and prevalence of mental illness in the workplace. Healthc Pap 2004; 5: 12–25 - PubMed
Publication types
MeSH terms
Grants and funding
- R01 DA016558/DA/NIDA NIH HHS/United States
- U01-MH60220/MH/NIMH NIH HHS/United States
- R03 TW006481/TW/FIC NIH HHS/United States
- R03-TW006481/TW/FIC NIH HHS/United States
- U01 MH060220/MH/NIMH NIH HHS/United States
- R13-MH066849/MH/NIMH NIH HHS/United States
- HHSN271200700030C/MH/NIMH NIH HHS/United States
- R01 MH070884/MH/NIMH NIH HHS/United States
- R01 MH059575/MH/NIMH NIH HHS/United States
- R13 MH066849/MH/NIMH NIH HHS/United States
- R01-MH059575/MH/NIMH NIH HHS/United States
- R01 MH069864/MH/NIMH NIH HHS/United States
- R01-MH61905/MH/NIMH NIH HHS/United States
- R01MH070884/MH/NIMH NIH HHS/United States
- R01 MH061905/MH/NIMH NIH HHS/United States
- R01-MH069864/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
